All Boehringer Ingelheim inhalers will be available for $35 a month for patients with commercial insurance and for those who do not have insurance.* Please visit www.Spiriva.com/Asthma/Registration for more information.*Terms and conditions apply. At retail pharmacies. Government restrictions exclude people enrolled in federal government insurance programs from $35 solutions.

Header
For Healthcare Professionals
skip to main
Boy Kicking Football with Coach Hero Banner

SPIRIVA RESPIMAT 1.25 mcg offers unparalleled support for your patients along their asthma treatment journey

Savings and support three cards
  • *
    Terms and Conditions Apply. 
    chevron external link
  • †
    Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 02/01/2024. Placement on formulary does not establish clinical comparability of products, including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it is subject to change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer Ingelheim Pharmaceuticals, Inc. does not sponsor or endorse any particular plan. Utilization controls/restrictions may vary from plan to plan. Provider communication only—not approved for prescription drug plan member distribution. Information is subject to change without notice.

Quick links

GET ACCESS

SPIRIVA RESPIMAT—the #1 prescribed LAMA among pulmonologists is also affordable1†‡

$35 Co-pay Savings

Eligible patients pay as little as $35 for a 30-day prescription fill with the SPIRIVA RESPIMAT Savings Card1‡

Sign up
Co-pay Card
  • †
    SPIRIVA RESPIMAT 1.25 mcg is the only LAMA indicated for the treatment of asthma.2

‡Terms and Conditions Apply.

chevron external link

LAMA, long-acting antimuscarinic agent.

Unrestricted access and best-in-class coverage for asthma1

SPIRIVA RESPIMAT has up to 92% aggregate access*

92% Aggregate Access With SPIRIVA RESPIMAT Inhalation Spray 1.25 mcg
  • *
    Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 02/01/2024. Placement on formulary does not establish clinical comparability of products, including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it is subject to change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer Ingelheim Pharmaceuticals, Inc. does not sponsor or endorse any particular plan. Utilization controls/restrictions may vary from plan to plan. Provider communication only—not approved for prescription drug plan member distribution. Information is subject to change without notice.

GET STARTED

Support and tools to help your patients with asthma start and stay on SPIRIVA RESPIMAT

FOR PATIENTS STARTING TREATMENT

The Choose the Mist Onboarding Kit helps patients get started on their RESPIMAT® inhaler successfully

  • Materials on how to use the RESPIMAT inhaler

  • Information on savings and support programs

  • Real stories from other patients

  • FAQs

Go to ChooseTheMist.com
RESPIMAT Mist Onboarding Kit

FOR PATIENTS ALREADY ON TREATMENT

Patients can receive ongoing, personalized support throughout their treatment journey at the Inhaleability HUB.

Go to Inhaleability.com
inhaleability HUB Personalized Support

Inhaleability HUB resources that help patients start and stay on treatment:

Local Air Quality Data Updated In Real Time

Local air quality data updated in real time for accuracy

Interactive MyActivity Tracker

The interactive MyActivity Tracker to help patients set and achieve goals

Tools And Helpful Resources

Tools and other helpful resources

INDICATION

SPIRIVA RESPIMAT, 1.25 mcg, is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older. SPIRIVA RESPIMAT is not indicated for relief of acute bronchospasm.

IMPORTANT SAFETY INFORMATION

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any component of this product. Immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported.

SPIRIVA RESPIMAT is intended as a once-daily maintenance treatment for asthma and should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. In the event of an attack, a rapid-acting beta2-agonist should be used.


Immediate hypersensitivity reactions, including urticaria, angioedema (including swelling of the lips, tongue, or throat), rash, bronchospasm, anaphylaxis, or itching may occur after administration of SPIRIVA RESPIMAT. If such a reaction occurs, discontinue SPIRIVA RESPIMAT at once and consider alternative treatments. Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to SPIRIVA RESPIMAT.


Inhaled medicines, including SPIRIVA RESPIMAT, may cause paradoxical bronchospasm. If this occurs, it should be treated with an inhaled short-acting beta2-agonist, such as albuterol. Treatment with SPIRIVA RESPIMAT should be stopped and other treatments considered.


SPIRIVA RESPIMAT should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop.


Since dizziness and blurred vision may occur with the use of SPIRIVA RESPIMAT, caution patients about engaging in activities such as driving a vehicle, or operating appliances or machinery.


SPIRIVA RESPIMAT should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.


Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) treated with SPIRIVA RESPIMAT should be monitored closely for anticholinergic side effects.


The most common adverse reactions >2% incidence and higher than placebo with SPIRIVA RESPIMAT (placebo) in asthma trials in adults were pharyngitis 15.9% (12.4%), headache 3.8% (2.7%), bronchitis 3.3% (1.4%), and sinusitis 2.7% (1.4%). The adverse reaction profile for adolescent and pediatric patients was comparable to that observed in adult patients with asthma.


SPIRIVA RESPIMAT may interact additively with concomitantly used anticholinergic medications. Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs.


Inform patients not to spray SPIRIVA RESPIMAT into the eyes as this may cause blurring of vision and pupil dilation.

Please see full Prescribing Information, including Instructions for Use, for SPIRIVA RESPIMAT.

CL-SVR-0044 2.15.2017

REFERENCES

  1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.

  2. SPIRIVA RESPIMAT [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; November 2021.